https://doi.org/10.55788/ccab8764
Advanced chronic kidney disease (CKD) is treated most effectively with kidney transplantation, which ultimately saves the healthcare system money from dialysis costs. Yet, due to access barriers, many kidney transplant-eligible patients will never receive a kidney transplant.
Dr Amit Garg (McMaster University, Canada) and colleagues designed a multicomponent intervention to address barriers that prevent kidney transplantation [1,2]. The components included administrative support, educational resources for healthcare professionals, patients, and donors, a patient support group called the ‘Transplant Ambassador Program,’ and reports on each patient’s progress. This was a “pragmatic, cluster-randomised trial to determine if renal programme-wide use of this multicomponent intervention was superior to usual care in helping eligible patients complete up to 4 key steps towards receiving a kidney transplant,” Dr Garg explained. The 4 steps were referral to a transplant centre, having a contact for living donor evaluation, addition to the donor waitlist, and receiving a transplant. All 26 CKD renal programmes in Ontario were randomly assigned to multicomponent intervention or usual care groups. Participants were 18 to 75 years old, had no recorded contraindication to transplantation, had an estimated glomerular flow rate <15 mL/min/1.73 m2, and had a >25% 2-year chance of receiving renal replacement therapy.
Approximately 10,000 participants were included in each group, and they were followed for a median of 2.1 years. The number of steps completed did not differ between the multicomponent intervention or usual care groups (HR 1.00; 95% CI 0.87–1.15). Dr Garg reflected that, even though the intervention did increase access to transplantation or living donation, the COVID-19 pandemic played a significant role in patients’ access, and he “believes that several aspects of our systems approach remain sensible.”
- Garg AX, et al. Effect of a Multi-Component Intervention to Improve Patient Access to Kidney Transplantation and Living Kidney Donation. FR-OR114, ASN Kidney Week 2023, 2–5 November, Philadelphia, PA, USA.
- Garg AX, et al. JAMA. 2023;Nov 3. DOI:10.1001/jamainternmed.2023.5802.
Copyright ©️2023 Medicom Medical Publishers
Posted on
Previous Article
« RMC-035 reduces long-term adverse kidney events following cardiac surgery Next Article
Donor stem cells may reduce lifelong immunosuppressant use following transplant surgery »
« RMC-035 reduces long-term adverse kidney events following cardiac surgery Next Article
Donor stem cells may reduce lifelong immunosuppressant use following transplant surgery »
Table of Contents: ASN 2023
Featured articles
Patient care technicians improve haemodialysis patient outcomes
Sparsentan outperforms irbesartan for treatment of IgAN
Chronic Kidney Disease
Aldosterone synthase inhibition reduces albuminuria in CKD
Low doses of zibotentan with dapagliflozin improve albuminuria in patients with CKD
Spironolactone failed to reduce major adverse cardiac effects in patients with CKD on haemodialysis
Efficacy of bardoxolone methyl for DKD, without increased cardiac risk
Renal Replacement Therapy
New approaches to successful vascular access
Patient care technicians improve haemodialysis patient outcomes
Donor stem cells may reduce lifelong immunosuppressant use following transplant surgery
A systems approach to kidney transplantation disappoints
Glomerular Disease
Obinutuzumab attenuates kidney decline in lupus nephritis
Clinical benefits of sparsentan for patients with FSGS
Sparsentan outperforms irbesartan for treatment of IgAN
Rare or Genetic Kidney Disease
Small molecule PGE1 shows promise for nephronophthisis treatment in vitro and in vivo
Related Articles
September 16, 2020
Transperineal laser ablation of prostate
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy